Tempest Therapeutics Ownership | Who Owns Tempest Therapeutics?

Tempest Therapeutics Ownership Summary

Tempest Therapeutics is owned by 6.73% institutional investors, 31.78% insiders, and 61.49% retail investors. Versant venture management is the largest institutional shareholder, holding 6.08% of TPST shares. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 0.81% of its assets in Tempest Therapeutics shares.

TPST Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Tempest Therapeutics	6.73%	31.78%	61.49%
Sector	Healthcare Stocks	244.59%	12.11%	-156.70%
Industry	Biotech Stocks	379.61%	11.70%	-291.31%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Versant venture management	269.77K	6.08%	$774.25K
Blackrock	550.24K	2.47%	$1.21M
Geode capital management	86.99K	2.10%	$142.67K
Vanguard fiduciary trust	68.91K	1.66%	$113.01K
Blackrock funding, inc. /de	39.07K	0.94%	$64.07K
Susquehanna group, llp	123.42K	0.48%	$103.00K
Sabby management	17.86K	0.43%	$29.28K
Northern trust	14.05K	0.34%	$23.05K
Bank of america corp /de/	43.26K	0.19%	$94.73K
Citadel advisors	29.60K	0.13%	$64.82K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Versant venture management	269.77K	0.51%	$774.25K
Sabby management	17.86K	0.07%	$29.28K
Tower research capital llc (trc)	2.79K	0.00%	$4.58K
National bank of canada /fi/	-	-	-
Engineers gate manager lp	-	-	-
Gsa capital partners llp	-	-	-
Drw securities	-	-	-
Blackrock	550.24K	-	$1.21M
Fil	-	-	-
Parallel advisors	18.00	-	$30.00

Top Buyers

Holder	Shares	% Assets	Change
Susquehanna group, llp	123.42K	-	78.16K
Vanguard fiduciary trust	68.91K	-	68.91K
Geode capital management	86.99K	-	42.88K
Blackrock	550.24K	-	42.05K
Citadel advisors	29.60K	-	16.10K

Top Sellers

Holder	Shares	% Assets	Change
Altium capital management lp	-	-	-545.00K
Jane street group	-	-	-493.09K
Vanguard group	-	-	-297.88K
Millennium management	-	-	-189.51K
Xtx topco	-	-	-160.81K

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	68.91K	-	68.91K	$113.01K
Global retirement partners	5.00	-	5.00	$4.00

Sold Out

Holder	Change
Whittier trust	-2.00
Jpmorgan chase	-5.00
Citigroup	-8.00
Whittier trust co of nevada	-11.00
Qube research	-27.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	19	-5.00%	1,024,557	98.12%	6	30.07%	8	14.29%	3	-
Mar 31, 2026	9	-55.00%	319,026	-59.49%	7	2.13%	4	-50.00%	1	-75.00%
Dec 31, 2025	1	-	269,772	-	6	12.07%	-	-	-	-
Sep 30, 2025	1	-50.00%	269,772	-8.70%	7	11.75%	-	-100.00%	-	-
Jun 30, 2025	2	-92.00%	295,494	-88.08%	7	25.24%	1	-90.91%	-	-100.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Institutional Extnd Mkt Idx Tr	128.94K	0.81%	-
Vanguard Morn Total Stk Mkt Idx Investor	104.94K	0.71%	-
Vanguard MStar Total Stk Mkt Idx Invest	104.94K	0.66%	-
Vanguard Total Stock Mkt Idx Inv	104.94K	0.66%	-
Fidelity Extended Market Index	48.45K	0.33%	-2.53K
Abante Quant Value FI	41.82K	0.28%	-
BlackRock Extended Equity Market K	36.10K	0.14%	-15.00
Fidelity Series Total Market Index	15.68K	0.11%	-
iShares Micro-Cap ETF	3.46K	0.10%	-
Spartan Extended Market Index Pool E	41.04K	0.09%	1.93K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 24, 2026	Angel Matthew	CEO and President	Buy	$500.00K
Mar 24, 2026	Angel Matthew	CEO and President	Buy	$500.00K
Mar 24, 2026	Angel Matthew	CEO and President	Buy	$500.00K
Aug 08, 2024	Versant Venture Capital VI, L.P.	-	Sell	$540.04K
Aug 12, 2024	Versant Venture Capital VI, L.P.	-	Sell	$426.99K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	1	-
2025 Q1	-	-
2024 Q3	2	2
2024 Q2	1	-
2024 Q1	-	-

TPST Ownership FAQ

Who Owns Tempest Therapeutics?

Tempest Therapeutics shareholders are primarily institutional investors at 6.73%, followed by 31.78% insiders and 61.49% retail investors. The average institutional ownership in Tempest Therapeutics's industry, Biotech Stocks , is 379.61%, which Tempest Therapeutics falls below.

Who owns the most shares of Tempest Therapeutics?

Tempest Therapeutics’s largest shareholders are Versant venture management (269.77K shares, 6.08%), Blackrock (550.24K shares, 2.47%), and Geode capital management (86.99K shares, 2.10%). Together, they hold 10.65% of Tempest Therapeutics’s total shares outstanding.

Does Blackrock own Tempest Therapeutics?

Yes, BlackRock owns 2.47% of Tempest Therapeutics, totaling 550.24K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.21M$. In the last quarter, BlackRock increased its holdings by 42.05K shares, a 8.27% change.

Who is Tempest Therapeutics’s biggest shareholder by percentage of total assets invested?

Versant venture management is Tempest Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.51% of its assets in 269.77K Tempest Therapeutics shares, valued at 774.25K$.

Who is the top mutual fund holder of Tempest Therapeutics shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of Tempest Therapeutics shares, with 0.81% of its total shares outstanding invested in 128.94K Tempest Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools